ProPhase Labs Inc. (PRPH)
0.61
-0.03 (-4.69%)
At close: Jan 14, 2025, 3:59 PM
0.61
0.00%
Pre-market Jan 15, 2025, 04:50 AM EST
undefined% (undefined)
| Bid | 0.57 |
| Market Cap | 14.63M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -0.4 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.64 |
| Volume | 236,069 |
| Avg. Volume (20D) | 260,347 |
| Open | 0.63 |
| Previous Close | 0.64 |
| Day's Range | 0.58 - 0.65 |
| 52-Week Range | 0.56 - 7.48 |
| Beta | undefined |
About PRPH
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also prov...
Sector Healthcare
IPO Date Apr 4, 1994
Employees 113
Stock Exchange NASDAQ
Ticker Symbol PRPH
Website https://www.prophaselabs.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PRPH stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 1695.63% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
ProPhase Labs Inc. is scheduled to release its earnings on Mar 14, 2025,
before market opens.
Analysts project revenue of $5.88M, reflecting a 35.14% YoY growth and earnings per share of -0.24, making a -52.94% decrease YoY.
Analysts project revenue of $5.88M, reflecting a 35.14% YoY growth and earnings per share of -0.24, making a -52.94% decrease YoY.
2 months ago ·
Source
+4.39%
ProPhase Labs shares are trading lower after the c...
Unlock content with
Pro Subscription
2 months ago ·
Source
-45.45%
ProPhase Labs shares are trading lower after the company announced a $3 million public offering of 4.17 million common shares at $0.72 per share.
